Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alcon (ALC) Total Liabilities (2018 - 2025)

Alcon has reported Total Liabilities over the past 10 years, most recently at $9.5 billion for Q4 2025.

  • Quarterly results put Total Liabilities at $9.5 billion for Q4 2025, up 8.26% from a year ago — trailing twelve months through Dec 2025 was $9.5 billion (up 8.26% YoY), and the annual figure for FY2025 was $9.5 billion, up 8.26%.
  • Total Liabilities for Q4 2025 was $9.5 billion at Alcon, up from $8.8 billion in the prior quarter.
  • Over the last five years, Total Liabilities for ALC hit a ceiling of $9.5 billion in Q4 2025 and a floor of $8.7 billion in Q4 2021.
  • Median Total Liabilities over the past 5 years was $9.0 billion (2023), compared with a mean of $9.1 billion.
  • Biggest five-year swings in Total Liabilities: rose 8.52% in 2022 and later fell 5.25% in 2023.
  • Alcon's Total Liabilities stood at $8.7 billion in 2021, then rose by 8.52% to $9.5 billion in 2022, then dropped by 5.25% to $9.0 billion in 2023, then decreased by 2.18% to $8.8 billion in 2024, then grew by 8.26% to $9.5 billion in 2025.
  • The last three reported values for Total Liabilities were $9.5 billion (Q4 2025), $8.8 billion (Q4 2024), and $9.0 billion (Q4 2023) per Business Quant data.